Loading...

FITC anti-mouse CD45.2 Antibody

Pricing & Availability
Clone
104 (See other available formats)
Regulatory Status
RUO
Other Names
Ly-5.2, LCA
Isotype
Mouse (SJL) IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
104_FITC_090507
C57BL/6 mouse splenocytes stained with 104 FITC
  • 104_FITC_090507
    C57BL/6 mouse splenocytes stained with 104 FITC
Compare all formats See FITC spectral data
Cat # Size Price Save
109805 50 µg ¥11,880
109806 500 µg ¥21,740
Description

CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
B10.S mouse thymocytes and splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation4, in vivo and in vitro blocking of B cell responses1,2, and immunohistochemical staining of acetone-fixed frozen sections3. 

Application References

(PubMed link indicates BioLegend citation)
  1. Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)
  2. Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)
  3. Suzuki K, et al. 2000. Immunity 13:691. (IHC)
  4. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
  5. Baldwin TA and Hogquist KA. 2007. J. Immunol. 179:837.
  6. Pascal V, et al. 2007. J. Immunol. 179:1751.
  7. Burman AC, et al. 2007. Blood 110:1064.
  8. Kincaid EZ, et al. 2007. J. Immunol. 179:3187.
  9. Phan TG, et al. 2007. Nature Immunol. 8:992.
  10. Nakano-Yokomizo T, et al. 2011. J. Exp Med. 208:1661. PubMed
  11. Wen T, et al. 2013. PNAS. 110:6067. PubMed
  12. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations
  1. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  2. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  3. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  4. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  5. Tian WJ, et al. 2021. Clin Exp Pharmacol Physiol. 48:902. PubMed
  6. He D, et al. 2022. Immunity. 55:159. PubMed
  7. Zhang D, et al. 2022. Cell Stem Cell. 29:232. PubMed
  8. Wang D, et al. 2022. Cell Rep. 39:110587. PubMed
  9. Jiang W, et al. 2022. Redox Biol. 56:102432. PubMed
  10. Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed
  11. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  12. De Giovanni M, et al. 2022. Cell. 185:815. PubMed
  13. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
  14. Coelho DR, et al. 2023. iScience. 26:106442. PubMed
  15. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  16. Michalova J, et al. 2011. Biol Blood Marrow Transplant. 17:1273. PubMed
  17. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  18. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  19. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
  20. Tan X, et al. 2016. PLoS One. 11: 0160985. PubMed
  21. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  22. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  23. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  24. Wei Q, et al. 2021. Nat Commun. 12:2522. PubMed
  25. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  26. Burman A, et al. 2007. Blood. 110:1064. PubMed
  27. Bhattacharjee S, et al. 2019. Cell Rep. 28:231. PubMed
  28. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  29. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  30. Swidergall M, et al. 2019. Cell Rep. 28:423. PubMed
  31. Atkin-Smith G, et al. 2017. Sci Rep. 7:39846. PubMed
  32. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  33. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  34. Liu Y, et al. 2021. Haematologica. Online ahead of print. PubMed
  35. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
  36. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  37. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  38. Emgård J, et al. 2018. Immunity. 143:419. PubMed
  39. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  40. Wang H, et al. 2019. Nat Commun. 10:1898. PubMed
  41. Schulz A, et al. 2019. Cell Rep. 29:1074. PubMed
  42. Guiducci E, et al. 2018. Front Immunol. 1.467361111. PubMed
  43. Zhang J, et al. 2022. iScience. 25:104963. PubMed
  44. Trompette A, et al. 2022. Mucosal Immunol. :. PubMed
  45. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  46. Kaplan BLF et al. 2018. Current protocols in toxicology. 75:11:00 25. PubMed
  47. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
  48. Li J, et al. 2020. Elife. 9:00. PubMed
  49. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  50. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  51. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  52. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  53. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  54. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  55. Faulhaber LD, et al. 2022. Neurophotonics. 9:031917. PubMed
  56. Wan X, et al. 2018. Nature. 560:107. PubMed
  57. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  58. Platteel A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.044. PubMed
  59. Abbott RK, et al. 2018. Immunity. 48:133. PubMed
  60. Bijalwan M, et al. 2019. Sci Rep. 9:3444. PubMed
  61. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  62. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  63. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  64. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  65. Huang D, et al. 2020. Nat Commun. 4.520833333. PubMed
  66. Leon-Rico D, et al. 2015. Lab Anim. 49:132. PubMed
  67. Stifter SA, et al. 2019. Cell Rep. 29:3539. PubMed
  68. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  69. Ma W, et al. 2017. Cell Death & Disease. 10.1038/cddis.2017.47. PubMed
  70. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  71. Burgess M, et al. 2014. Blood. 124:3947. PubMed
  72. Kesavardhana S, et al. 2020. J Biol Chem. 295:8325. PubMed
  73. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  74. Zhang W, et al. 2022. Nat Methods. 19:759. PubMed
  75. Zeis P, et al. 2020. Immunity. 53:775. PubMed
  76. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  77. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  78. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  79. de Laval B, et al. 2020. Cell Stem Cell. 26(5):657-674. PubMed
  80. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  81. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  82. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  83. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  84. Jaako P, et al. 2016. Leukemia. 10.1038/leu.2016.159. PubMed
  85. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  86. Kissiov DU, et al. 2022. Elife. 11:. PubMed
  87. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  88. Düking T, et al. 2022. Sci Adv. 8:eabo7639. PubMed
  89. Ma L, et al. 2022. Sci Adv. 8:eabm3470. PubMed
  90. Koide S, et al. 2022. iScience. 25:103603. PubMed
  91. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  92. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  93. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  94. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  95. Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed
  96. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  97. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  98. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  99. Ubags ND, et al. 2021. J Allergy Clin Immunol. 1049:147. PubMed
  100. Bosma M, et al. 2016. Nat Commun. 7: 11314. PubMed
  101. Andresen L, et al. 2016. PLoS One. 11: 0148428. PubMed
  102. Zhang J, et al. 2019. Exp Hematol. 78:21:00. PubMed
  103. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  104. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  105. Halvarsson C, et al. 2019. Antioxid Redox Signal. 31:211. PubMed
  106. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  107. Hung LY, et al. 2019. J Immunol. 203:511. PubMed
  108. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  109. Stienstra R, et al. 2014. Diabetes. 63:4143. PubMed
  110. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  111. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  112. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  113. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  114. Hsieh WC, et al. 2018. Nat Commun. 9:463. PubMed
RRID
AB_313442 (BioLegend Cat. No. 109805)
AB_313442 (BioLegend Cat. No. 109806)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Suzuki K, et al. 2000. Immunity 13:691.

Gene ID
19264 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD45.2
Specificity Alt (DOES NOT SHOW ON TDS):
CD45.2
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD45.2 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45.2 Reagents Request Custom Conjugation
Description Clone Applications
Biotin anti-mouse CD45.2 104 FC
FITC anti-mouse CD45.2 104 FC
PE anti-mouse CD45.2 104 FC
Purified anti-mouse CD45.2 104 FC,Block,IHC-F,IP
APC anti-mouse CD45.2 104 FC
Alexa Fluor® 488 anti-mouse CD45.2 104 FC
Alexa Fluor® 647 anti-mouse CD45.2 104 FC
Pacific Blue™ anti-mouse CD45.2 104 FC
Alexa Fluor® 700 anti-mouse CD45.2 104 FC
APC/Cyanine7 anti-mouse CD45.2 104 FC
PerCP anti-mouse CD45.2 104 FC
PerCP/Cyanine5.5 anti-mouse CD45.2 104 FC
PE/Cyanine7 anti-mouse CD45.2 104 FC
Brilliant Violet 421™ anti-mouse CD45.2 104 FC
Brilliant Violet 570™ anti-mouse CD45.2 104 FC
Brilliant Violet 650™ anti-mouse CD45.2 104 FC
Brilliant Violet 510™ anti-mouse CD45.2 104 FC
Brilliant Violet 785™ anti-mouse CD45.2 104 FC
Brilliant Violet 605™ anti-mouse CD45.2 104 FC
Purified anti-mouse CD45.2 (Maxpar® Ready) 104 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45.2 104 FC
Brilliant Violet 711™ anti-mouse CD45.2 104 FC
Alexa Fluor® 594 anti-mouse CD45.2 104 IHC-F,SB
APC/Fire™ 750 anti-mouse CD45.2 104 FC
TotalSeq™-A0157 anti-mouse CD45.2 104 PG
TotalSeq™-B0157 anti-mouse CD45.2 104 PG
TotalSeq™-C0157 anti-mouse CD45.2 104 PG
Brilliant Violet 750™ anti-mouse CD45.2 104 FC
Spark Blue™ 550 anti-mouse CD45.2 104 FC
Spark NIR™ 685 anti-mouse CD45.2 104 FC
Spark UV™ 387 anti-mouse CD45.2 104 FC
Spark Blue™ 574 anti-mouse CD45.2 (Flexi-Fluor™) 104 FC
Spark Red™ 718 anti-mouse CD45.2 (Flexi-Fluor™) 104 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account